港股異動 | 維亞生物(1873.HK)逆勢大漲7%盤中破頂 獲南下資金持續加倉
格隆匯8月7日丨維亞生物(1873.HK)盤中急漲至10%再創新高,現報10.72港元,漲6.99%,暫成交2.3億港元,最新總市值201.1億港元。維亞生物日前夥和鉑醫藥孵化創新生物藥企,維亞生物總裁任德林表示,合作將進一步拓展維亞生物商業模式的可延展性。另外,在9月底攜手Schrödinger,就共同研發全新靶點結構達成戰略合作。據格隆匯APP顯示,近期持續獲南下資金加倉,港股通最新持股比例已升至10.57%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.